Greater than the sum of its parts: Partner with CCAB on your antibody-drug conjugate project
It’s that time of year when many people will be walking, running and working hard to raise awareness and money for various cancers. A significant portion of the funds raised will be used to support research that will expand our understanding of these diseases, helping to develop more effective, targeted therapies.
For instance, one of the challenges of current chemotherapies is that while they are powerful treatments that kill cancer cells, they do not differentiate between cancer cells and healthy ones. The result? Healthy cells are also damaged, leading to undesirable, sometimes severe side effects.
Emerging from the efforts to develop more targeted therapies are antibody-drug conjugates (ADCs). ADCs are a highly potent therapy, engineered to kill only cancer cells while sparing healthy ones. They are a combination of:
- monoclonal antibodies,
- a cytotoxic drug, and
- linker molecules that attach the cytotoxic drug securely to the antibody and break only when the drug is inside cancer cells.
Move your project forward with CCAB’s antibody science expertise
Designing an ADC is a complex process. Key to the success of the therapy is the antibody component that targets a specific protein on the surface of cancer cells and serves as the foundation of ADCs.
CCAB has extensive expertise in the production of synthetic antibodies. CCAB’s academic research partner, the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto, has a state-of-the-art protein engineering research platform that enables the generation of therapeutic-grade antibodies against virtually any target. Through TRAC, CCAB has access to an extensive portfolio of high-value antibodies against many cancers. These antibodies can be immediately used by CCAB partners for proof-of-concept projects.
Currently, CCAB is working with industry partners on ADC projects, including:
- Supporting the development of fully-human therapeutic antibodies against ImmunoBiochem’s lead cancer target. Immunobiochem is focusing on developing new treatments for patients with triple-negative breast cancer, an aggressive disease with poor survival and that does not respond to major therapies.
- Licensing validated antibody candidates to Advanced Proteome Therapeutics for the development of ADCs as potential treatments for cancer. The company is developing a proprietary technology that is designed to site-selectively attach drugs to antibody surfaces.
Contact us to learn how we can work with you to accelerate your ADC project.